Sign in

Audrey D. Zhang

@audreydzhang.bsky.social
575 followers 470 following 947 posts

Primary care physician and health services researcher. General medicine fellow at Harvard/BIDMC. Studying how to improve health care delivery for older adults. linktr.ee/audreydzhang

PostsRepliesMedia
Reposted by Audrey D. Zhang
AcademyHealth @academyhealth.bsky.social · 16/07/2026
AHRQ grant cancellations are no longer theoretical, they're happening. We've heard from many researchers and institutions affected by notices ending continuation funding for ongoing projects. Read what we know so far, why these cancellations matter, and how we're responding.
buff.ly
AHRQ Has Begun Canceling Research Grants. Here's What We Know.
Researchers across the country have begun receiving official notices from AHRQ informing them that continuation funding for their grants will not be awarded.
037
Audrey D. Zhang @audreydzhang.bsky.social · 30/05/2026
Looking forward to sharing our work on how telemedicine waiver expiration could contribute to increased burden of in-person care in older adults, recently published in @jamanetworkopen.com: jamanetwork.com/journals/jam...
Screenshot of slide titled "Telemedicine Reimbursement Changes and Health Care Contact Days for Older Adults"
031
Audrey D. Zhang @audreydzhang.bsky.social · 08/05/2026
Great to present our work on the potential impact of telemedicine waiver expiration on increasing in-person burden of care for older adults in traditional Medicare at #SGIM26!
110
Audrey D. Zhang @audreydzhang.bsky.social · 08/05/2026
How would older adults’ burden of care change if Medicare telemedicine waivers expired? Our new @jamanetworkopen.com study examines this question among older adults in traditional Medicare. With @katemmorgan.bsky.social @ishaniganguli.bsky.social: jamanetwork.com/journals/jam...
jamanetwork.com
Telemedicine Reimbursement Changes and Health Care Contact Days for Older Adults
This cross-sectional study examines the extent to which telemedicine days experienced by traditional Medicare beneficiaries may supplement in-person health care contact days and how telemedicine waive...
141
Reposted by Audrey D. Zhang
Kara Gavin @karagavin.bsky.social · 10/04/2026
Attention all who have ever received AHRQ funding to fuel #healthcare research: You have 6 days left to submit expert testimony to the House Appropriations Committee as they consider the agency's future funding. @academyhealth.bsky.social has tips: ahsituationreport.substack.com/p/academyhea...
ahsituationreport.substack.com
AcademyHealth Action Resource: Submit Testimony to Congress on AHRQ Funding
Our new resource offers tips and best practices to help you contact lawmakers and advocate for a fully-funded AHRQ.
023
Reposted by Audrey D. Zhang
Miranda Yaver @mirandayaver.bsky.social · 08/04/2026
My book Coverage Denied: How Health Insurers Drive Inequality is out on 4/23! It’s available through @cambup-polsci.cambridge.org and Amazon, Strand, Powell’s, etc. Out in less than 3 weeks, it combines survey & interview research to explain health ins barriers. www.cambridge.org/core/books/c...
cambridge.org
Coverage Denied
Cambridge Core - Epidemiology Public Health and Medical Statistics - Coverage Denied
27422
Audrey D. Zhang @audreydzhang.bsky.social · 27/06/2025
🚨 New paper: As a PCP, I often hear from patients that managing their health care feels like a full-time job. To understand this better, we analyzed the first nationally-representative US survey of older adults’ self-reported treatment burden: agsjournals.onlinelibrary.wiley.com/doi/10.1111/...
agsjournals.onlinelibrary.wiley.com
Treatment Burden Among Older Adults in the United States, 2022
Background Treatment burden refers to the patient-perceived effort of managing health and health care, which impacts quality of life and engagement in care. International studies of treatment burden...
35320
Audrey D. Zhang @audreydzhang.bsky.social · 24/06/2025
ICYMI, out in print this week. While we framed this Viewpoint with optimism, it can conversely be said that eroding health survey infrastructure means we’re flying a little more blind each day on priorities like chronic disease, maternal health, and substance use: jamanetwork.com/journals/jam...
jamanetwork.com
Enhancing Health Survey Infrastructure for Chronic Disease
This Viewpoint discusses an opportunity to promote safeguarding, expanding, and modernizing the national health survey infrastructure as a crucial part of a comprehensive approach to address chronic d...
041
Reposted by Audrey D. Zhang
Ezra Golberstein @egolberstein.bsky.social · 01/04/2025
NSDUH is one of the only ways we can track trends in substance use in the US. NSDUH is one of the only ways we can track adolescent mental health problems in the US. We cannot afford to fly blind on these critical issues.
612765
Reposted by Audrey D. Zhang
Ezra Golberstein @egolberstein.bsky.social · 19/03/2025
One big thing that AHRQ does is run the Medical Expenditures Panel Survey. This may sound like a trivial thing if you are outside the field. But the Congressional Budget Office relies on this information when modeling health policy changes. That is a huge deal.
35627
Audrey D. Zhang @audreydzhang.bsky.social · 20/02/2025
Many more pieces like this could be written to show the impact of sustained federal investment in US biomedical research. This one has a great table highlighting the role of NIH funding in some of our greatest gains against chronic disease in the past 80 years. www.ahajournals.org/doi/full/10....
Table: Ten key advances in CVD and stroke research funded by the NIH. Advances: Framiningham Heart Study, tPA treatment for ischemic stroke, statin therapy for CVD prevention, CRT for heart failure, RCTs for blood pressure management, improving care of children with heart conditions, developing and evaluating stents for treating coronary artery disease, gene editing for CVD, lifestyle interventions to reduce CVD risk, precision medicine
062
Reposted by Audrey D. Zhang
Carl T. Bergstrom @carlbergstrom.com · 08/02/2025
1. Today the NIH director issued a new directive slashing overhead rates to 15%. I want to provide some context on what that means and why it matters. grants.nih.gov/grants/guide...
grants.nih.gov
NOT-OD-25-068: Supplemental Guidance to the 2024 NIH Grants Policy Statement: Indirect Cost Rates
NIH Funding Opportunities and Notices in the NIH Guide for Grants and Contracts: Supplemental Guidance to the 2024 NIH Grants Policy Statement: Indirect Cost Rates NOT-OD-25-068. OD
25469994078
Reposted by Audrey D. Zhang
Library Innovation Lab @harvardlil.bsky.social · 06/02/2025
We just launched a 16TB archive of every dataset that has been available on data.gov since November. This will be updated day by day as new datasets appear. It can be freely copied, and we're sharing the code behind it to help others make their own archives of data they depend on.
lil.law.harvard.edu
Announcing the Data.gov Archive | Library Innovation Lab
Today we released our archive of data.gov on Source Cooperative. The 16TB collection includes over 311,000 datasets harvested during 2024 and 2025, a complet...
4219011000
Audrey D. Zhang @audreydzhang.bsky.social · 14/01/2025
The intensity and seriousness of cancer care has prompted attention to the wide-ranging impact of "time toxicity" of care on patients and caregivers. We would benefit from improved understanding of such burdens and their tradeoffs in other areas as well: jamanetwork.com/journals/jam...
jamanetwork.com
Patient, Caregiver, and Clinician Perspectives on Time Burdens of Cancer Care
This qualitative analysis explores time-consuming aspects of cancer care that were perceived as burdensome, identifies the individuals most affected by the time burdens of cancer care, and evaluates t...
041
Audrey D. Zhang @audreydzhang.bsky.social · 13/01/2025
"If someone had asked us in the summer of 2021 what we most needed to facilitate Mom’s healing and well-being, our wish list would have been modest." So often our health care system fails to live up to its name of providing care: www.healthaffairs.org/doi/full/10....
healthaffairs.org
The Idea Of A Good Daughter | Health Affairs Journal
A public health professor and her mother failed to receive long-term care support from the health care system when they needed it most.
165
Reposted by Audrey D. Zhang
Jay Van Bavel, PhD @jayvanbavel.bsky.social · 27/12/2023
Want to see if your research has had an impact on public policy? Enter your info in SagePolicyProfiles to see the citations of your own publications in policy documents. You get a profile page. Here is mine as an example: policyprofiles.sagepub.com/profile/5920...
411444
Reposted by Audrey D. Zhang
Michael L. Barnett @mlbarnett.bsky.social · 02/12/2024
I didn't know any of this policy story - worth the read. TL;DR 1980s regulatory changes enabled monopsony behavior by big chains, basically destroying the small local grocer.
1134
Reposted by Audrey D. Zhang
John Graves @johngraves.bsky.social · 25/11/2024
As the baby boom generation enters its prime years for long-term care needs, its difficult to come up with a more challenging backdrop than an immigration system about to be cut off at its knees (think: nursing home aides) and states having to fill in funding gaps from Medicaid spending shortfalls.
915770
Audrey D. Zhang @audreydzhang.bsky.social · 16/11/2024
A lot to think about in this review from a research perspective - what are the essential components of the underlying concept of "decision fatigue"? How do we operationalize that definition? How does this concept apply not only to clinicians, but to patients and caregivers?
010
Audrey D. Zhang @audreydzhang.bsky.social · 27/10/2023
#NewLitHighlights #HealthPolicy Nurse practitioners and physician assistants are now responsible for over a quarter of outpatient visits in traditional Medicare - still a lot of room to understand how to optimize their role in clinical care: www.bmj.com/content/382/...
120
Audrey D. Zhang @audreydzhang.bsky.social · 11/10/2023
Great advice on making the most of the shifts between clinical and research time as a clinician-investigator, applicable to folks at multiple levels. Wish I'd seen some of these tips before learning them the hard way! (via @BryantShuey) jamanetwork.com/journals/jam...
jamanetwork.com
Preparing to Attend on the Inpatient Medical Wards
Transitions are a way of life in academic medicine. While much has been written about these changes, less attention has been devoted to a more common shift: the
001
Reposted by Audrey D. Zhang
Loren Adler @lorenadler.bsky.social · 06/10/2023
If you've got any research (even in the pipeline) that might help better understand the effects of anti-obesity medications on health care and other federal spending, CBO wants to see it: www.cbo.gov/publication/...
023
Audrey D. Zhang @audreydzhang.bsky.social · 06/10/2023
Not so many people here discussing #FDAPolicy #RxPolicy yet, but this one will be one to follow - for the first time, FDA exercises its FDORA power to expedite withdrawal of drugs initially approved via accelerated approval: www.bloomberg.com/news/article... #HealthPolicy
bloomberg.com
FDA Tests New Power to Pull Some Fast-Tracked Drugs Off Market
Its first target is a cancer treatment from Oncopeptides given accelerated approval in 2021, which has since faced a study questioning its effectiveness.
064
Reposted by Audrey D. Zhang
Adrianna McIntyre @adrianna.bsky.social · 26/09/2023
PSA: deck.blue is basically a clone of Tweetdeck for BlueSky—it even lets you curate personal lists, independent of feeds If you haven't used any bsky apps before, you need to create an "app password" (under Settings > Advanced) to log in
0197
Audrey D. Zhang @audreydzhang.bsky.social · 03/10/2023
This looks like it will be an excellent opportunity to better understand how a wide and diverse range of people contribute to dementia care and its associated outcomes - I'll be looking forward to getting my hands in the data.
120
Audrey D. Zhang @audreydzhang.bsky.social · 01/10/2023
#HiSciSky! I'm an #PrimaryCare physician and health services researcher studying prescribing and medication use to improve quality of care for older adults. Interests include #GIM #Geriatrics #Deprescribing #RxEpi #HealthPolicy #RxPolicy. Looking forward to connecting with friends old and new!
0243
Reposted by Audrey D. Zhang
Aaron Schwartz @aschwartz.bsky.social · 21/09/2023
Any time you are tempted to dismiss descriptive research as unimportant, keep in mind: a medical diagnosis is a description. "You have lymphoma" seems like an important thing to know, right? Describing our world is important.
142
Audrey D. Zhang @audreydzhang.bsky.social · 01/11/2022
Great to see our recent study covered in ⁦@statnews⁩ by @TaraBannow⁩ - we found over 1/3 of both physicians and APCs received industry payments in 2021: www.statnews.com/2022/10/31/advance…
statnews.com
Advanced practice clinicians slightly more likely to take...
A slightly higher share of advanced practice clinicians t...
000
Audrey D. Zhang @audreydzhang.bsky.social · 31/10/2022
We know industry payments to physicians are common, but what about the nurse practitioners, physician assistants, and other APCs critical to patient care? New paper out in @JAMA_current with @TimAndersonMD: jamanetwork.com/journals/jama/fulla…
100
Audrey D. Zhang @audreydzhang.bsky.social · 19/06/2022
"Recommendations for outcome measurement for deprescribing intervention studies" (@DeprescribeUS Measures Working Grp) - lack of standardization in deprescribing measures poses challenges to interpretation, with many opportunities for further development:...
110
Audrey D. Zhang @audreydzhang.bsky.social · 18/06/2022
“Moving Deprescribing Upstream” (@michelleskeller @SarahVordenberg @MikeSteinman) - or as I've started to think of it, "the process of deprescribing begins with prescribing": link.springer.com/article/10.1007/s…
000
Audrey D. Zhang @audreydzhang.bsky.social · 14/06/2022
Pair with this new study led by @jeromie_b with a different approach to estimating @CMSGov spending on “dangling” accelerated approval drugs/indications without full approval (~$1-2B in 2019): www.acpjournals.org/doi/10.7326/M21…
000
Audrey D. Zhang @audreydzhang.bsky.social · 14/06/2022
Catching up on new paper from @SkydelJ on @CMSGov spending on drugs approved by @US_FDA Accelerated Approval pathway - huge sum ($60+B/9y) involved, most for drugs with unconfirmed benefit or “confirmed” with surrogate endpoints only:...
100
Audrey D. Zhang @audreydzhang.bsky.social · 13/05/2022
Great to see lots of interest in the recent aducanumab saga at policy update with @Aging_MD at #AGS22. For those still here, I’ll be presenting at Sat 5/13 HSR Paper Session on representativeness of trial participants along the pipeline of anti-amyloid mAbs for AD:
000
Audrey D. Zhang @audreydzhang.bsky.social · 12/05/2022
Have been thinking a lot recently about this point highlighted by @VouriPharmD - #deprescribing is often framed as a geriatric issue but the framework is applicable in many settings beyond: #AGS22
000
Audrey D. Zhang @audreydzhang.bsky.social · 12/05/2022
Obesity care is primary care - appreciate focus on interventions beyond behavioral ones. We have options! And important to remember potential role of obesogenic medications - new study showing high prevalence among people who are overweight/obese:...
100
Audrey D. Zhang @audreydzhang.bsky.social · 12/05/2022
Great general principle to keep in mind with #BeersCriteria update at #AGS2022 - discontinuation of a drug is not equivalent to avoiding initiation of a drug. Early exploration in subgroup analysis of ASPREE and ripe for further investigation:...
100
Audrey D. Zhang @audreydzhang.bsky.social · 12/05/2022
Proposed #BeersCriteria update on antipsychotics at #AGS2022 spurring a lot of comments/discussion on appropriate conditions for use - recognizing trade-offs and nuances of meeting multiple patient goals including remaining in the community:
000
Audrey D. Zhang @audreydzhang.bsky.social · 12/05/2022
Proposed 2022 #BeersCriteria changes presented at #AGS2022 - notably to antiplatelet/anticoagulation recs:
000
Audrey D. Zhang @audreydzhang.bsky.social · 11/05/2022
Inspiring @DeprescribeUS #USDeN2022Live keynote by Dr. Barbara Farrell on developing guidelines for the process of #deprescribing:
100
Audrey D. Zhang @audreydzhang.bsky.social · 11/05/2022
Great start to @DeprescribeUS #USDeN2022Live meeting! @MikeSteinman highlights gap in research on deprescribing in communities of color - an opportunity for further #pharmacoequity research. @UREssien
000
Audrey D. Zhang @audreydzhang.bsky.social · 06/04/2022
Excited to be heading to #SGIM22 - first in-person conference in 3 years! Thanks to @SocietyGIM for sponsoring me as a Young Scholar in GIM. Looking forward to the next few days with my academic home. #ProudtobeGIM
000
Audrey D. Zhang @audreydzhang.bsky.social · 17/03/2022
Huge amount of FDA-related legislation up for discussion before @EnergyCommerce, including on clinical trial representation and Accelerated Approval reform - hearing @ 10:30 AM today:...
100
Audrey D. Zhang @audreydzhang.bsky.social · 11/03/2022
"Attitudes toward deprescribing among older adults with dementia in the United States" (@matthew_growdon, @MikeSteinman) - adds to our understanding of nuanced attitudes towards polypharmacy and deprescribing in people with dementia:...
110
Audrey D. Zhang @audreydzhang.bsky.social · 10/03/2022
"Outcome Measures for Interventions to Reduce Inappropriate Chronic Drugs: A Narrative Review" (@aubert_carole @EveKerrMD) - chronic drug deprescribing studies use wide variety of measures; room to standardize and esp. develop clinically-relevant outcomes:...
100
Audrey D. Zhang @audreydzhang.bsky.social · 03/03/2022
"Evaluating the use of prescription sequence symmetry analysis as a pharmacovigilance tool: A scoping review" (@DrEarlIV, @VouriPharmD) - new-to-me neat self-controlled method of identifying/testing prescribing cascades:...
100
Audrey D. Zhang @audreydzhang.bsky.social · 28/02/2022
Late to this - @TheWonkologist @peterbachmd examine 30 years of FDA policy through the lens of PDUFA - which allowed industry to gain negotiating power on FDA policy through the FDA budget:...
100
Audrey D. Zhang @audreydzhang.bsky.social · 24/01/2022
Great panel @UCStanfordCERSI summit on future of accelerated approval, especially discussion w/r/t generating confirmatory evidence (esp. important in light of recent Aduhelm decision):...
100
Audrey D. Zhang @audreydzhang.bsky.social · 11/01/2022
Great to see draft @CMSGov decision to use the CED pathway and cover aducanumab only in the context of an RCT - driving forward the rigorous collection of further data and evidence for efficacy and safety: www.statnews.com/2022/01/11/medicar…
statnews.com
Medicare plans to restrict access to controversial, price...
Medicare took a highly unusual step to restrict access to...
000